H. Lee Moffitt Cancer Center and Research Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, H. Lee Moffitt Cancer Center and Research Institute sits in the top decile of US sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count).
H. Lee Moffitt Cancer Center and Research Institute: 502 sponsored US clinical trials, 82 recruiting.
H. Lee Moffitt Cancer Center and Research Institute sponsors 502 registered US clinical trials on ClinicalTrials.gov, 82 of them currently recruiting, and 280 completed. 5 of these trials are in Phase 3-4 (later-stage) and 335 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
H. Lee Moffitt Cancer Center and Research Institute ranks in the top decile of sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
280 of 344 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
502 total, page 4 of 11
Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
NCT02415621
Development of a Mindfulness-Based Smartphone Application for BMT Caregivers
NCT07352943
PRehabilitation Intervention to Modify Eating for Breast Cancer Patients (PRIME)
NCT07638150
Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors
NCT07487168
Modifying Diet to Improve Gut Microbiome
NCT03924778
Evaluation and Outcomes of SAVI Scout MD for Localized Breast Surgery
NCT07686250
Wet Heparinized Suction for Abdominal Cancer
NCT05041335
Intermittent Fasting for Pancreatitis
NCT04760847
Mindfulness-Based Ecological Momentary Intervention For Smoking Cessation Among Cancer Survivors
NCT06476548
Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer
NCT06378047
Cancer Coaching and Remote Education for Self-Empowerment (CARES) Study
NCT06323291
Aim 1: App for Reducing Cravings to Smoke
NCT06923033
Enhancing Cancer Survivorship With Pickleball
NCT06048822
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
NCT05704933
Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC
NCT05873439
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
NCT05316116
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
NCT05694364
STRONG Program for Cancer Patients
NCT05649969
Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy
NCT05579847
Exploring Men s Prostate Cancer Genetic Risk Perceptions
NCT06764992
Caregiver Protocol for Remotely Improving, Monitoring, and Extending Quality of Life
NCT05379933
Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
NCT05127174
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
NCT05065866
Comparing Pre-Anesthesia Evaluation Via Telemedicine Versus in Person for Surgical Patients at Moffitt Cancer Center
NCT05065944
SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
NCT05093608
CARES-HCV: Promoting Screening Uptake Among Diverse Baby Boomers
NCT04980157
Effect of Prolonged Nightly Fasting on Immunotherapy Outcomes in HNSCC - Role of Gut Microbiome
NCT05083416
COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
NCT05054218
Adaptation Of An HPV Education Resource To Promote HPV Vaccination
NCT04974619
Clinical Trials Outreach & Education
NCT05064423
Motivating a Spectrum of Cancer Patients to Quit Smoking
NCT04914000
Project HEALS (Helping and Empowering pAtients for Living a Life Smoke-free
NCT05362318
Study to Develop a Group-Based E-Health Intervention for YA Cancer Survivors
NCT05048316
Health Beliefs, Behaviors, and Healthcare Experiences Among United States Young and Mid-Age Adults
NCT04766164
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML
NCT04620681
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
NCT04526730
Addressing Barriers to Palliative Care Use in Bladder Cancer
NCT04598724
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
NCT04610658
Evaluation of EnVisio SmartClip for Intraoperative Localization of Breast Masses
NCT04604561
Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC
NCT04610671
SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
NCT04596579
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
NCT04242173
Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes
NCT04319237
Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE
NCT04150874
Electronic Social Network Assessment Program (eSNAP) + Caregiver Navigator
NCT04268979
Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk
NCT04257474
Feasibility Study for Electroacupuncture for Chemotherapy- Induced Peripheral Neuropathy (CIPN)
NCT04092764
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
NCT04191187
TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
NCT04163718
Utilizing Augmented Reality as an Adjunct for Smoking Cessation
NCT04101422
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 167 |
| Phase 2 | 168 |
| Phase 3 | 3 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the H. Lee Moffitt Cancer Center and Research Institute pipeline
82 recruiting of 502 indexed (16% open); 280 completed (56%).
Phase mix: 5 late (III/IV) vs 335 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
H. Lee Moffitt Cancer Center and Research Institute: open-pipeline peers nationwide
Peers matched on 502 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
H. Lee Moffitt Cancer Center and Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 502 trials (± recruiting share)
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- Boehringer Ingelheim · 515 trials · 8% recruiting
Sponsors near 16% open enrollment (± trial volume)
- Case Western Reserve University · 16% recruiting · 141 trials
- Drexel University · 16% recruiting · 92 trials
- Atlantic Health System · 16% recruiting · 43 trials
- BioMarin Pharmaceutical · 16% recruiting · 80 trials
Related
What to do with this H. Lee Moffitt Cancer Center and Research Institute page
502 registered trials is a research-attention snapshot, not an endorsement of H. Lee Moffitt Cancer Center and Research Institute or any single study.
- 82 of H. Lee Moffitt Cancer Center and Research Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition H. Lee Moffitt Cancer Center and Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
H. Lee Moffitt Cancer Center and Research Institute pipeline card: 502 registered trials from official public datasets.Report a data error.